Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051324 · ClinicalTrials.gov registry record
Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
A clinical trial of Huntington Disease, sponsored by Jordan Schultz.
- Active
- Registry status
- 1,700
- Enrollment target
- 1
- Study location
NCT00051324: Active study of Huntington Disease, sponsored by Jordan Schultz.
NCT00051324 is a study of Huntington Disease that is active but no longer recruiting, run by Jordan Schultz. The registered enrollment target is 1,700 participants, above the 587-participant average among 35 other Huntington Disease trials with a reported enrollment target (190% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051324, a study of Huntington Disease, is active but no longer recruiting, sponsored by Jordan Schultz.
- ACTIVE NOT RECRUITING
- Registry status
- 1,700 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.
Primary Outcome
HD diagnosis will be better predicted by adding longitudinal change to the baseline measures of striatal and white matter volumes, tone-paced and speeded tapping score, stroop interference and motor score.
Conditions Studied
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2002-08 |
| Est. Completion | 2025-06-30 |
What the registry record for NCT00051324 still lists
NCT00051324 is an observational study that tracks outcomes without assigning an intervention. Its 1,700 participants enrollment target places it among the larger protocols in the corpus, above the 587-participant average among 35 other Huntington Disease trials with a reported enrollment target (190% higher).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00051324 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT00051324 about?
NCT00051324 is a clinical study titled "Neurobiological Predictors of Huntington's Disease (PREDICT-HD)". The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.
What is the current status of trial NCT00051324?
This trial is currently active not recruiting. The enrollment target is 1,700 participants. The study started on 2002-08. Estimated completion is 2025-06-30.
What conditions does trial NCT00051324 study?
This clinical trial studies the following conditions: Huntington Disease.
Who is sponsoring clinical trial NCT00051324?
This trial is sponsored by Jordan Schultz, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051324 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00051324's enrollment target sits among peer trials
1,700 4th of 35 higher than 32 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia